Hospital de la Santa Creu i de Sant Pau

Barcelona 8025

4 studies enrolling now · 12 studies all time

What they study most

Breast Cancer, Chemotherapy-induced Peripheral Neuropathy, Clear Cell Renal Cell Carcinoma (ccRCC), Colorectal Cancer (CRC), Community-acquired Pneumonia, Cushing's Disease, Diabetes Mellitus, Type 1, HNSCC, HRAS Gene Mutation, NASH - Nonalcoholic Steatohepatitis, Non Clear Cell Renal Cell Carcinoma (nccRCC), Non Small Cell Lung Cancer (NSCLC)

Studies at this site

• Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP) — Recruiting now
• A Trial of Lu AG13909 in Adult Participants With Cushing's Disease — Recruiting now
• KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors — Recruiting now
• Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients — Recruiting now
• A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis — Running, not enrolling
• A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia — Completed
• Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer — Running, not enrolling
• Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC — Completed
• DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer — Running, not enrolling
• Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy) — Running, not enrolling
• Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy — Completed
• Gan & Lee Evaluation of New Biosimilar for Type 1 Lispro — Withdrawn before enrolling